<DOC>
	<DOC>NCT01122251</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure. The study will investigate the dose response relationship for the combinations and monotherapies.</brief_summary>
	<brief_title>Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lercanidipine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Patients aged between 20 and 75 Essential hypertension at screening (3 week) Randomization Criteria: Essential hypertension at baseline (90mmHg≤sitDBP≤109mmHg, except sitSBP≥180) Mean sitDBP≥110mmHg or sitSBP≥180 Secondary hypertension or suspected secondary hypertension Uncontrolled diabetes Severe heart disease or severe cerebrovascular disease clinically significant hematological test results, renal disease (serum creatinine) or liver disease (ALT or AST) History of malignant disease Autoimmune disease Women with a positive pregnancy test result, breast feeding or intention of pregnancy during the trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>hypertension</keyword>
	<keyword>lercanidipine</keyword>
	<keyword>valsartan</keyword>
</DOC>